Clinical Scorecard: Comparative Effectiveness of Ampicillin-Sulbactam and Ceftriaxone for Treating Community-Acquired Pneumonia in Elderly Patients: Insights from a Target Trial Emulation Analysis

At a Glance

Key Highlights

• Ampicillin-sulbactam was associated with higher in-hospital mortality compared to ceftriaxone (10.5% vs 9.0%)
• Incidence of Clostridioides difficile infection was numerically higher with ampicillin-sulbactam (0.6% vs 0.4%)
• Routine anaerobic coverage is not recommended in current guidelines unless lung abscess or empyema is suspected

Guideline-Based Recommendations

Diagnosis

• Diagnosis of CAP based on clinical and radiological criteria; bacterial pneumonia diagnosis sensitivity ~63%, specificity ~94.8% in DPC database

Management

• Initial empirical treatment options include ampicillin-sulbactam or ceftriaxone
• Routine anaerobic coverage is unnecessary in suspected aspiration pneumonia unless lung abscess or empyema is present
• Ceftriaxone preferred over ampicillin-sulbactam due to lower mortality and lower risk of C. difficile infection

Monitoring & Follow-up

• Monitor for in-hospital mortality and development of Clostridioides difficile infection during hospitalization

Risks

• Higher mortality risk associated with ampicillin-sulbactam compared to ceftriaxone
• Increased risk of Clostridioides difficile infection with extended anaerobic coverage regimens

Patient & Prescribing Data

Older adults (≥65 years) hospitalized with community-acquired pneumonia

Ceftriaxone demonstrated lower adjusted in-hospital mortality and lower incidence of C. difficile infection compared to ampicillin-sulbactam

Clinical Best Practices

• Avoid routine anaerobic coverage in CAP unless clinical suspicion of lung abscess or empyema
• Consider ceftriaxone as initial empirical therapy for hospitalized older adults with CAP
• Use target trial emulation frameworks to assess real-world effectiveness of treatments
• Monitor patients closely for signs of C. difficile infection during antibiotic therapy

References

• 2019 and 2023 CAP Guidelines on Anaerobic Coverage
• Target Trial Emulation Methodology
• Real World Data Database Description
• Clostridioides difficile Infection Risk with Antibiotics